## Summary minutes of the 8th Institutional Review Board Meeting in FY2021 (Expedited review)

Date & time Monday, August 30, 2021, 10.00 – 12.20

Place Auditorium (Hiroshima) and the 3rd Conference Room (Nagasaki)

Participants IRB co-chairpersons: Dr. Tanabe and Ms. Shinohara

IRB members: Dr. Yamada, Dr. Satoh, Dr. Hida, Ms. Ogawa, Ms. Dodo, and Mr. Fuchi

## < Review of research involving human subjects >

	Dept.	Study title	Review result	Summary minutes
1	Epidemiology	Revision to RP-S2-19  "The mediating effects of tobacco use and alcohol consumption on the incidence of related solid cancers among the Life Span Study of atomic bomb survivors (Dekker <i>et al.</i> )"	Approved	<ol> <li>Update information on the researcher's affiliations and roles so they are current.</li> <li>Revise the time span of the research protocol.</li> <li>Add Vanderbilt University as an institution data will be shared with.</li> <li>Add a note that a record of data provision will be kept, and how to keep it.</li> <li>The phrasing in Japanese on line 9 of page seven in the meeting materials, "dose will be in the closest mGy," should adhere to the English version, "radiation doses to three significant digits."</li> <li>Delete the first two sentences in "4) Consultation from the Subjects": As the study data are anonymized and information is not disclosed to the subjects, consultation of individual information by the subjects will not be accepted. General inquiries about the study may be accepted.</li> <li>The form used for Information Disclosure Based on the Guidelines should be changed to Form 1-5-2, and then the new form should be appended as part of the research protocol.</li> <li>The date of approval should be written on the research protocol.</li> </ol>

## < Field survey of FY2021 human genome/gene analysis research (interviews with investigators) >

	Dept.	Study title	Review result	Summary minutes
1	Clinical Studies	RP 1-17 "Detection of the onset of hematological malignancy among atomic bomb survivors" (Imaizumi <i>et al.</i> )	Approved	<ol> <li>An application for revisions should be submitted if the study period needs to be extended.</li> <li>The implementation status report's "Other information" section should detail the consent information obtained from the five subjects.</li> </ol>
2	Molecular Biosciences	RP-P1-19 "Preliminary Study to determine the applicability of Wright-stained blood smear samples in GWAS" (Hayashi <i>et al.</i> )	Approved	The implementation status report's "Other information" section should detail the consent information obtained from the six subjects.

## < Review of ethical survey on ongoing research projects >

	Dept.	Study title	Review result	Summary minutes
1	All departments	Review of research projects below minimum risk	Approved	<ol> <li>We will have the study periods written in date format for non-platform research RPs from now on.</li> <li>Have the IRB's executive secretaries prepare a list for the study periods of research protocols to check their current statuses. If a study period is nearing or has already reached its end, we will have procedures for applying for either an extension or completion be taken.</li> </ol>

<sup>\*</sup>Approved by confirming that the aforementioned revisions have duly been made.

<sup>\*</sup>To prevent the spread of COVID-19, the IRB members at the meeting maintained sufficient distances from each other.